Skip to main content
SpringerLink
Log in

Beunruhigender Befund

Die nicht-alkoholische Fettleber-Erkrankung

Non-alcoholic fatty liver disease (NAFLD)

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Die nicht-alkoholische Fettleber-Erkrankung (NAFLD) ist die am stärksten zunehmende Lebererkrankung weltweit. Und nicht nur die Leber ist gefährdet: Die NAFLD ist ein unabhängiger Risikofaktor für die Entstehung von Herz-Kreislauf- und extrahepatischen Tumorerkrankungen. Zudem drohen eine Insulinresistenz und eine Störung des Fettstoffwechsels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature reviews Gastroenterology & hepatology 2018;15:11–20

    Article  Google Scholar 

  2. Younossi ZM, Blissett D, Blissett R et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–86

    Article  Google Scholar 

  3. Mikolasevic I, Filipec-Kanizaj T, Mijic M et al. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol. 2018;24:1491–1506

    Article  Google Scholar 

  4. Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clinical liver disease. 2018;11:92–4

    Article  Google Scholar 

  5. Younossi Z, Tacke F, Arrese M et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69:2672–82

    Article  Google Scholar 

  6. Bedogni G, Miglioli L, Masutti F et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology. 2007;46:1387–91

    Article  Google Scholar 

  7. Mann JP, Anstee QM. NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD. Nature reviews Gastroenterology & hepatology. 2017;14:506–7

    Article  Google Scholar 

  8. Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84

    Article  Google Scholar 

  9. Allen AM, Therneau TM, Larson JJ et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2018;67:1726–36

    Article  CAS  Google Scholar 

  10. Tesfay M, Goldkamp WJ, Neuschwander-Tetri BA. NASH: The Emerging Most Common Form of Chronic Liver Disease. Missouri medicine. 2018;115:225–9

    PubMed  PubMed Central  Google Scholar 

  11. Dulai PS, Singh S, Patel J et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65:1557–65

    Article  CAS  Google Scholar 

  12. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. Journal of hepatology. 2019;70:531–44

    Article  Google Scholar 

  13. Labenz C, Prochaska JH, Huber Y et al. Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. Hepatol Commun. 2019;3:1472–81

    Article  CAS  Google Scholar 

  14. Labenz C, Huber Y, Michel M et al. Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Digestive diseases and sciences. 2019; in press

    Google Scholar 

  15. Huber Y, Boyle M, Hallsworth K et al. Healthrelated Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clin gastroenterol hepatol. 2019;17:2085–92

    Article  Google Scholar 

  16. Singh S, Allen AM, Wang Z et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin gastroenterol hepatol. 2015;13:643–54; e641—49; quiz e639—40

    Article  Google Scholar 

  17. Mantovani A, Dauriz M, Byrne CD et al. Association between nonalcoholic fatty liver disease and colorectal Tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and metaanalysis. Metabolism: clinical and experimental 2018; https://doi.org/10.1016/j.metabol.2018.06.004

    Google Scholar 

  18. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASLEASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J hepatol. 2016;64:1388–1402

    Google Scholar 

  19. Roeb E, Steffen HM, Bantel H et al. S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol. 2015;53:668–723

    Article  CAS  Google Scholar 

  20. Vilar-Gomez E, Martinez-Perez Y, CalzadillaBertot L et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367–78;e365;quiz e314—65

    Article  Google Scholar 

  21. Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–90

    Article  CAS  Google Scholar 

  22. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New Engl J Med. 2010;362:1675–85

    Article  CAS  Google Scholar 

  23. Bril F, Biernacki DM, Kalavalapalli S et al. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes care. 2019;42:1481–8

    Article  CAS  Google Scholar 

  24. Younossi Z, Ratziu V, Loomba R et al. GS06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. J hepatol. 2019;70:e5

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. I. Medizinische Klinik, Universitätsmedizin Mainz, Langenbeckstrasse 1, D-55131, Mainz, Deutschland

    Jörn M. Schattenberg

Authors
  1. Jörn M. Schattenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörn M. Schattenberg.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schattenberg, J.M. Die nicht-alkoholische Fettleber-Erkrankung. MMW - Fortschritte der Medizin 162, 56–62 (2020). https://doi.org/10.1007/s15006-020-0004-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-020-0004-z

Keywords

Search

Navigation